Navigation Links
Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target

New study demonstrates 75% of patients receiving highest dose achieves A1c with no associated hypoglycemia

CHICAGO, June 25, 2007 /PRNewswire-FirstCall/ -- According to findings presented today at the 67th Scientific Sessions of the American Diabetes Association (ADA) in Chicago, Illinois, the investigational treatment liraglutide, a once- daily dose of human GLP-1 analog under development by Novo Nordisk for the treatment of type 2 diabetes significantly improved glycemic control (A1c) by reducing both fasting and post-meal glucose levels in people with type 2 diabetes. The Phase 2 study included 226 Japanese patients with type 2 diabetes treated over a period of 14 weeks. Results showed that liraglutide was effective and well tolerated within a wide dose range, allowing nearly 75 percent of patients receiving the highest dose to achieve glycemic control (A1c<7.0%) without hypoglycemia.(1)

"One challenge with insulin and many oral antidiabetic agents, which boost insulin secretion or heighten insulin sensitivity, is that they can lower blood glucose levels, resulting in hypoglycemia, which can sometimes be dangerous," said Professor Yutaka Seino, Director of Kansai-Denryoku Hospital and professor, Department of Metabolism & Clinical Nutrition, Graduate School of Medicine, Kyoto University, and lead investigator on the trial. "A well- tolerated agent with once-daily administration that can allow a majority of patients to achieve good glycemic control with a low risk of hypoglycemia and no weight gain is very promising and will be a considerable advance in diabetes treatment."

Liraglutide acts to lower blood glucose when levels are elevated, and previous studies have shown it is associated with a low risk of hypoglycemia.(2)(3)

About the Study (Abstract #0520-P)

In the study, 226 Japanese type 2 diabetes patients treated with diet or a single oral anti-diabetic drug, discontinued
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:7/2/2015)... , July 2, 2015 Numotion,s Board of ... announced that Tamas Feitel has joined the ... Numotion after a highly successful 18 year career at ... driving strategy, profitability, and productivity to result in significant ... position was Chief Financial Officer for GE Healthcare Global ...
(Date:7/2/2015)... 2, 2015   Decision Resources Group ... identify less frequent dosing as the highest unmet ... the burden on both patients and providers associated ... (VEGF) injections, which are the current standard of ... which is in development for dosing every two ...
(Date:7/2/2015)... , July 2, 2015 ... (Homofermentative & Heterofermentative), Species (Lactobacillus, Pediococcus & Enterococcus), Enzymes ... and Forecast to 2020", Silage Inoculants & Enzymes Market ... a CAGR of 4.0% from 2015 to 2020. ... igures spread through 194 P ...
Breaking Medicine Technology:Numotion Names Tamas Feitel Chief Financial Officer 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 2Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 4
... Sept. 1 There has been recent,concern that ... Montelukast is a Food and Drug Administration (FDA) ... than a decade for the treatment of,asthma and ... the,American Lung Association has found no evidence of ...
... CMS, Inc., an Elekta Company and,worldwide ... management,solutions, today announced that three sites have ... Modulated,Radiotherapy (IMRT) treatment planning system. Allegheny General ... Rotterdam,Netherlands, and Froedtert Memorial Lutheran Hospital in ...
Cached Medicine Technology:American Lung Association Study Finds No Evidence of Depression or Suicide Linked to Asthma and Allergy Drug Montelukast 2American Lung Association Study Finds No Evidence of Depression or Suicide Linked to Asthma and Allergy Drug Montelukast 3CMS, Inc., an Elekta Company, Announces First Cancer Patients Treated With Monaco(TM) Radiation Treatment Planning System 2
(Date:7/4/2015)... ... July 04, 2015 , ... Tyler Boden, Project ... technical sales expertise from the North American Board of Certified Energy Practitioners (NABCEP®), ... most highly respected and well established national certification organization for renewable energy professionals. ...
(Date:7/3/2015)... ... July 03, 2015 , ... ... on July 2nd creating a buzz of media attention. In an effort to ... by HonestyFirstReviews.com's Tiffany Hendricks. , "These days many people are feeling overwhelmed by ...
(Date:7/3/2015)... ... July 03, 2015 , ... ... 2015 Annual Conference , the premiere continuing education and networking event ... at SeaWorld in Orlando, Florida. Speakers include the leading rheumatology experts in ...
(Date:7/3/2015)... ... July 03, 2015 , ... Renowned rhinoplasty surgeon and Symposium Chairman, ... Dallas Rhinoplasty Symposium . To be held from March 4th - 6th, the 2016 ... the Westin Galleria Dallas. , Designed to take participants from the basic training and ...
(Date:7/3/2015)... Lenexa, KS (PRWEB) , ... July 03, 2015 ... ... firm dedicated exclusively to healthcare providers, has been retained to lead a national ... Okla. One of the top-ranked executive search firms in the healthcare industry, B. ...
Breaking Medicine News(10 mins):Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 3Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 2Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 3Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 2Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 3Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3
... smoking the first cigarette in the morning, the more difficult ... Yale School of Medicine study in Drug and Alcohol Dependence. ... found significant reductions in craving, withdrawal and mood after smoking ... reduction, the more likely the smoker would relapse, said Benjamin ...
... patients of the superbug MRSA - by treating their foot ... his team used green bottle fly larvae to treat 13 ... found all but one were cured within a mean period ... the conventional treatment. ,Professor Boulton, who published the ...
... developing a brain disease similar to mad cow disease, according ... Academy of Neurology's 59th Annual Meeting in Boston, April 28 ... cow disease, and chronic wasting disease, are fatal and there ... when an animal eats the body parts of other animals ...
... made headway in the development of an investigative blood ... to develop complications in the bone marrow, leading to ... Brisbane's Mater Medical Research Institute (MMRI) and Sydney's West ... a simple blood test to detect such tendencies. ...
... companies is not happy with the proposal to fortify all ... the state and federal governments to veto this proposal. ... enhance the foliate levels in women of child-bearing age. The ... spina bifida. ,If you ask Ian Greenshields from ...
... both get high blood pressure and related kidney disease, the path ... men , researchers say. ,They may end up ... could be very different, says Dr. Jennifer C. Sullivan, pharmacologist/physiologist ... ,Its known that men tend to develop hypertension earlier ...
Cached Medicine News:Health News:Reduction in Nicotine Craving Predicts Ability to Quit 2Health News:Maggots Rid Patients of MRSA 2Health News:Vaccine Prevents Prion Disease in Mice 2Health News:Cause of Gender Differences in Blood Pressure, Kidney Damage Under Study 2Health News:Cause of Gender Differences in Blood Pressure, Kidney Damage Under Study 3
McIntyre-Binkhorst Cannula have a smooth blunt tip end opening....
Army navy retractor set....
Sharp. 4 mm wide. Hand-Held...
Adsons bayonet forceps....
Medicine Products: